Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
about
The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseasesNeutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of MyeloperoxidaseThe Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and DiseaseReactive Oxygen Species: A Key Hallmark of Cardiovascular DiseaseLow serum myeloperoxidase in autistic children with gastrointestinal diseaseMyeloperoxidase: a front-line defender against phagocytosed microorganismsMonocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques.Oxidative risk for atherothrombotic cardiovascular disease.A Phytochemical-rich Multivitamin-multimineral Supplement Is Bioavailable and Reduces Serum Oxidized Low-density Lipoprotein, Myeloperoxidase, and Plasminogen Activator Inhibitor-1 in a Four-week Pilot trial of Healthy Individuals.Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjectsMyeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina.Myeloperoxidase-derived oxidation: mechanisms of biological damage and its preventionExposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysisGrowing significance of myeloperoxidase in non-infectious diseases.Resveratrol confers protection against rotenone-induced neurotoxicity by modulating myeloperoxidase levels in glial cellsAssociation of blood monocyte and platelet markers with carotid artery characteristics: the atherosclerosis risk in communities carotid MRI study.Decreased plasma myeloperoxidase associated with probiotic therapy in autistic children.Induction of indoleamine 2, 3-dioxygenase in human dendritic cells by a cholera toxin B subunit-proinsulin vaccine.Analysis of the association between adiponectin, adiponectin receptor 1 and diabetic cardiomyopathyReactive oxygen species in cardiovascular disease.Dual functionality of myeloperoxidase in rotenone-exposed brain-resident immune cells.Myeloperoxidase modulation by LDL apheresis in familial hypercholesterolemiaThe human myeloperoxidase gene is regulated by LXR and PPARalpha ligands.Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.Tripping up Trp: Modification of protein tryptophan residues by reactive oxygen species, modes of detection, and biological consequencesThe ARIC carotid MRI study of blood cellular markers: an inverse association of monocyte myeloperoxidase content with peripheral arterial disease.Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetesMUNC13-4 protein regulates the oxidative response and is essential for phagosomal maturation and bacterial killing in neutrophils.Role of VPO1, a newly identified heme-containing peroxidase, in ox-LDL induced endothelial cell apoptosis.Antioxidant effects of vitamins C and e on the low-density lipoprotein oxidation mediated by myeloperoxidase.Myeloperoxidase: a target for new drug development?Host defenses against respiratory tract infection: implications for anti-inflammatory drug development and treatment.Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortiaLow-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.Superoxide anion production by human neutrophils activated by Trichomonas vaginalis.Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.Myeloperoxidase, modified lipoproteins, and atherogenesis.Regulation of reactive oxygen species generation in cell signaling.Preconditioning with Azadirachta indica ameliorates cardiorenal dysfunction through reduction in oxidative stress and extracellular signal regulated protein kinase signalling.
P2860
Q24655891-6A123D17-78B5-4FDA-B2C6-5304DD798205Q26767149-6CABDEAA-3C06-48DC-B24C-067F03AD67C3Q26780548-81493000-257B-443B-B30B-7C1E99841087Q28076240-EFAFF6E3-710F-4BB9-8A1A-A073E4499721Q28241398-BD64E0E9-E12F-48C6-8EFA-BEC24A88759CQ28393101-F5A9C0CE-05F7-412D-BD9F-229A237F8D56Q33473042-7A59DDC8-FEDF-452D-9B92-29163AFC81E9Q33554184-DDA48A56-C4CE-46E1-B4D1-2223E7BDF0B6Q33570079-8674813A-E03C-4F89-8BF0-8AE3CDC99A48Q33575669-3DA5162F-5939-4A7D-A813-F61DE5ED3EB4Q33723943-E80678D4-3956-45EC-B0E2-18B2A41EE3AEQ34072878-AB2223C0-9882-47BA-9A4A-F284724752F5Q34162955-94C737CE-06F4-4255-8A82-1B494E0C506AQ34313976-7D463395-2F51-46A2-834E-22B29805C418Q34578402-0E8B477F-31B7-469E-BD2D-CDE617E29B40Q34673645-5F58A2B5-F39B-4C7D-ABE7-EA1DDD0D6A34Q34898589-20227E59-9944-43FB-A772-8B8808317BB7Q35057148-99C8D5D4-2E7E-40EF-9E98-B359D6E6AA40Q35122841-C5C33B17-F99C-4848-8123-D9D754DD0DE2Q35131663-1D6568C2-F5BE-4AA6-9587-C30B8F1F1D2BQ35165194-A3E0B7DA-C752-4351-8BD9-7C354A7EBA28Q35167895-9BCCC37C-4372-4912-B508-30DA1D7A25AAQ35541075-2FD520AA-7DE7-4EF4-BD59-5F011C078D5FQ35697554-1A1B1749-634C-440E-B7FE-FEFDCFD2DB8EQ35909357-FA4B0F6D-1C90-47C6-911E-79B868609AEBQ36386406-2917F613-0721-47F6-BC11-9DDF138FF242Q36388947-83BF9486-B8DE-44AD-8F4B-F62266F44905Q36417045-F82C8858-9285-4BC3-92FA-07FCAC16890CQ36492893-38629848-F17A-4BF0-BC73-3AC7A2A3FC06Q36603272-C5741FD9-8B8D-4415-9E04-A226B2263F47Q36694448-C227AD50-4DA6-42BA-9914-368F5C6917B2Q36860606-9936C1B0-EA7C-4704-A4ED-FB68F74ACA70Q37030665-38321E70-992D-4742-B072-74C06965682AQ37045120-F1104DA5-B918-40C2-A8E6-8BFAA070EE98Q37091275-113DE21E-C2D6-4CEF-8E94-33F4E2AF0FC2Q37165151-1F86BC29-69C2-4ACA-8797-EE7051428ED4Q37286296-E14682E1-5EA1-4FE4-B485-D74C3BA3F8F1Q37353408-A8690C1A-B2FD-4A89-89B8-8775919A7676Q37461363-11DB348D-5FD8-4BD3-B277-24EA603D4D7AQ37538978-12CD919F-40DC-43E3-A133-412ECFE2583B
P2860
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@ast
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@en
type
label
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@ast
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@en
prefLabel
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@ast
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@en
P2093
P356
P1433
P1476
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
@en
P2093
Devaquet P
Vanderstocken G
P356
10.1159/000041062
P577
2000-01-01T00:00:00Z